News
New study about antidepressants – Big Pharma and medical agency working close together to save profits and careers
The news that antidepressants in actual fact don’t work better than sugar pills and increase the risk for suicide have filled major media the last year. Psychiatrists, Big Pharma and medical agencies, responsible for distorting the facts for many years, are now working hard to save profits and careers.
The new study, “A Regulatory Apologia - A review of placebo controlled studies of new-generation antidepressants”, claiming that antidepressants work well for all forms of depression should be seen in that light. It’s another good example of how alleged objective medical agencies work close together with the pharmaceutical industry and its paid psychiatrists to increase sales.
The study was announced in the journal of the Swedish Medical Association (Läkartidningen)
In the article Beerman with pride announced the new study from the MPA; a study supposed to prove his statements. The study was said to be submitted for publication in the most prestigious medical journal on the planet, the Lancet.
But this part of the story needs to be told:
What Beerman didn’t say (April 15) was that the Lancet already, almost two weeks earlier, (April 4) had rejected the article – it was not to be published. The MPA then made another try, and submitted the data to the British Medical Journal (BMJ) – another journal with high impact. But the response was the same, the BMJ rejected the material.
So the agency – with its for Big Pharma so important “research message” – went directly to the manufacturers, or more correctly to a journal with an editor-in-chief who probably has meant more for the approval and sales of antidepressant drugs internationally than anyone else: The agency submitted its article to European Neuropsychopharmacology, with its editor-in-chief, Dr. Stuart Montgomery. And it was accepted.
For those not familiar with the work of Dr. Montgomery it can be said that he played a major role in helping Big Pharma to get new antidepressant drugs approved in the beginning of the 90-ties (despite that the actual data already at that time showed the drugs gave an increased risk of suicide). He was also responsible for the famous concealment of Seroxat/Paxil severe withdrawal symptoms. Instead of accepting the clear withdrawal symptoms so that patients and doctors could be warned Dr. Montgomery and colleagues misclassified these symptoms as signs of recurring depression – needing more drug treatment.
So a study with the PR-message that antidepressants work well for all forms of depression would most likely be very welcome in the European Neuropsychopharmacology. And it was. One of the reviewers of the article made the point very clear, saying: “This meta-analysis is very timely in the situation when the recent meta-analysis of Kirsch et al. (2008) induced a lot of uncertainty about the efficacy of antidepressants, both in the psychiatric community as well as in public opinion.” It was recommended that the article should be published “without any delay, given the situation mentioned above [“uncertainty … in the psychiatric community as well as in public opinion”].”
The MPA and its counterpart FDA have done almost nothing to use the wealth of data in its files to show the actual suicide risks with antidepressants, and to warn doctors and the public. (See the newly unsealed extensive analysis by Dr. Joseph Glenmullen of GlaxoSmithKline’s hiding of Seroxat/Paxil suicide data, as an example of how the pharmaceutical industry can act, and how ineffective and silent a regulatory agency can be in questioning the data in the drug applications http://finance.senate.gov/press/Gpress/2008/prg061208a.pdf , 4MB.) The lack of positive drug effects has always been denied by the MPA. The ineffective system for postmarketing surveillance of adverse drug effects is putting the public at severe risk – yet it is allowed unchanged year after year. The often horrible withdrawal symptoms of antidepressant drugs have been explained away as signs of recurring depression – and thus transformed to evidence of positive drug effects; and this manipulation has been accepted by the regulatory agencies. The MPA and the FDA, supposed to protect the public, are agencies out of control, and see the pharmaceutical industry as their real clients.
It’s first in a situation, where independent analyses of data submitted to the FDA show no positive effect of antidepressant drugs compared to placebo, that the Swedish MPA puts all its “research resources” in action to prove the opposite. The eagerness for collaborating with Big Pharma in getting out a PR-message, to handle the “uncertainty about the efficacy of antidepressants, both in the psychiatric community as well as in public opinion”, is yet another example of betrayal of the real clients – the public.
Janne Larsson
Reporter – investigating psychiatry
More News
Young Women, Antidepressants and Suicide A report on the situation in Sweden 2013
We have read in the media that “psychiatric disorders” and the number of suicides are increasing among young women. This increase is in Sweden parallel with a heavy increase in the prescription of antidepressants and other psychiatric drugs to yo ...
Released On: 12/9/2014
Views: 5137
Research fraud, prisoners and ADHD drugs in Sweden
The study was hailed in media and used for new prescription guidelines. But the actual disastrous results were concealed. No one – except the researchers involved – knew that 26% of the subjects receiving the “ADHD drug”
Released On: 11/11/2014
Views: 8491
ADHD drug Concerta disapproved for adults in Europe
The European medical agencies have disapproved the ADHD drug Concerta for adults. The well selected short-term clinical trials did not hold: No certain positive effects; clear evidence that Concerta can cause anxiety and agitated conditions in ad ...
Released On: 10/7/2011
Views: 15536
ADHD: Strattera Death Count Continued – 137 Reports of Deaths, 57 were Children
Released On: 11/7/2010
Views: 7647
Renowned Psychiatry Professor Helped Forest Labs Cover up Bad Results of Antidepressant in Children
Released On: 3/30/2010
Views: 4131
Confidential report reveals: Big Pharma trying to stop long-term safety studies of ADHD drugs (Ritalin, Concerta)
Released On: 3/5/2010
Views: 11684
Official warnings issued: The ADHD drug Strattera CAUSES psychosis, hallucinations, mania and agitation
Released On: 12/2/2008
Views: 17602
New data shows antidepressants and neuroleptics involved in 77 percent of reported suicides
Released On: 8/8/2008
Views: 4165
New study about antidepressants – Big Pharma and medical agency working close together to save profits and careers
Released On: 6/26/2008
Views: 5422
The ADHD drug Strattera: Lilly to issue warnings about psychosis, hallucinations, mania and agitation
Released On: 4/28/2008
Views: 3379
National data: Psychiatric drugs behind 75 percent of all female suicides
Newly uncovered data show that psychiatric drugs were behind 75 percent of ALL suicides among women (18-84) in Sweden (2006); antidepressants were behind 52 percent.
Released On: 2/7/2008
Views: 4482
Antidepressants behind 52 percent of all suicides among women
Released On: 1/22/2008
Views: 15810
Reported suicides – more than 80 percent got psychiatric drugs, well over 50 percent got antidepressants
Released On: 10/7/2007
Views: 10771
The endocrine effects of the psychiatric drug Zyprexa are extremely dangerous, says Swedish Professor in Psychiatry
Released On: 9/13/2007
Views: 5221
Map
larsson telia.com
Get Directionslarsson telia.com
-
Snöbollsgränd 22
Hägersten, Stockholm 12945
Sweden - 0094687089342
